Glenmark Pharmaceuticals Ltd. on Wednesday announced that it has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India.
The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg).
On Tuesday, Boehringer Ingelheim’s Empagliflozin became off-patent in India. Major domestic drugmakers are expected to launch their generic versions soon.
According to the company’s statement, these medications are designed to improve glycemic control in adults with Type 2 Diabetes while also reducing cardiovascular outcomes in patients with heart disease risk.
Empagliflozin is a globally established treatment for heart failure and diabetes, offering multiple benefits like cardiovascular and renal safety.
“Glenmark has a strong legacy of introducing innovative and accessible treatments for Cardiometabolic care in India. The launch of Glempa range reinforces this commitment by providing a comprehensive and affordable solution that empowers healthcare professionals and patients to manage Type 2 Diabetes with established CVD more effectively,” Alok Malik, President and Head of India Formulations Business, Glenmark Pharmaceuticals Ltd., said.
Glenmark’s Glempa range is designed to cater to diverse patient needs by offering three treatment options that enhance treatment flexibility and effectiveness. Glempa (Empagliflozin 10mg/25mg) serves as a standalone SGLT2 inhibitor to improve glycaemic control while reducing cardiovascular risks.
Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) is a dual-action therapy combining an SGLT2 inhibitor with a DPP4 inhibitor for more effective management of T2DM with cardio renal risks.
Meanwhile, Glempa M (Empagliflozin 12.5 mg + Metformin 500/1000 mg) combines the benefits of SGLT2 inhibition with the proven efficacy of Metformin, making it an optimal choice for patients needing stronger glycemic control.
With Cardiovascular diseases and diabetes cases on the rise, Glenmark’s Glempa range aims to provide affordable, high-quality treatment options, improving health outcomes for millions of patients across India, the company said in a statement.
